Cymbalta and Debility - a phase IV clinical study of FDA data
Summary:
We study 155,208 people who take Cymbalta (duloxetine hydrochloride) or have Debility. No report of Debility is found in people who take Cymbalta.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Cymbalta?
Cymbalta has active ingredients of duloxetine hydrochloride. It is often used in depression. eHealthMe is studying from 154,971 Cymbalta users. Check the latest studies of Cymbalta.
What is Debility?
Debility (physical weakness) is found to be associated with 4 drugs and 24 conditions by eHealthMe. Check the latest studies of Debility.
No report is found.
Do you take Cymbalta and have Debility?
- Check whether Debility is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Cymbalta:
- Cymbalta (154,971 reports)
Debility treatments and more:
- Debility (237 reports)
How severe was Debility and when was it recovered:
Expand to all the drugs that have ingredients of duloxetine hydrochloride:
Browse all side effects of Cymbalta:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Debility:
Browse all the conditions that are associated with Debility:
How the study uses the data?
The study uses data from the FDA. It is based on duloxetine hydrochloride (the active ingredients of Cymbalta) and Cymbalta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Hydrocodone Bitartrate And Ibuprofen vs. Nucynta Er, side effect and effectiveness comparison - 9 seconds ago
- Drug interactions of Diphen and Vitamin B-6 - 11 seconds ago
- Could Clobazam cause Insomnia? - 15 seconds ago
- Symbicort and Orthostatic Hypotension for Men aged 60+ - 16 seconds ago
- Could Omega-3 cause Blood Pressure Diastolic Decreased? - 17 seconds ago
- Could Viibryd cause Hot Flushes Aggravated? - 22 seconds ago
- Drug interactions of Leuprolide Acetate and Amoxicillin - 26 seconds ago
- Lopurin and Hospitalisation for Women aged 40-49 - 28 seconds ago
- Drug interactions of Allopurinol and Furosemide - 28 seconds ago
- Drug interactions of Mobic and Salagen - 30 seconds ago